[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2003303591A1 - Pharmaceutical compositions with improved dissolution - Google Patents

Pharmaceutical compositions with improved dissolution

Info

Publication number
AU2003303591A1
AU2003303591A1 AU2003303591A AU2003303591A AU2003303591A1 AU 2003303591 A1 AU2003303591 A1 AU 2003303591A1 AU 2003303591 A AU2003303591 A AU 2003303591A AU 2003303591 A AU2003303591 A AU 2003303591A AU 2003303591 A1 AU2003303591 A1 AU 2003303591A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
improved dissolution
dissolution
improved
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003303591A
Inventor
Orn Almarsson
Hongming Chen
Hector Guzman
Mark Oliveira
Matthew Peterson
Julius Remenar
Mark Tawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transform Pharmaceuticals Inc
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/601,092 external-priority patent/US20050025791A1/en
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/en
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from PCT/US2003/028982 external-priority patent/WO2004026235A2/en
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Priority claimed from PCT/US2003/041273 external-priority patent/WO2004061433A1/en
Publication of AU2003303591A1 publication Critical patent/AU2003303591A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicinal Preparation (AREA)
AU2003303591A 2002-12-30 2003-12-24 Pharmaceutical compositions with improved dissolution Abandoned AU2003303591A1 (en)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US43751602P 2002-12-30 2002-12-30
US60/437,516 2002-12-30
US44133503P 2003-01-21 2003-01-21
US60/441,335 2003-01-21
US45121303P 2003-02-28 2003-02-28
US60/451,213 2003-02-28
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
US45660803P 2003-03-21 2003-03-21
US60/456,608 2003-03-21
US45950103P 2003-04-01 2003-04-01
US60/459,501 2003-04-01
US10/601,092 2003-06-20
US10/601,092 US20050025791A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
AUPCT/US2003/019574 2003-06-20
PCT/US2003/019574 WO2004000284A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
US48706403P 2003-07-11 2003-07-11
US48671303P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
US60/486,713 2003-07-11
AU2003272270 2003-09-04
PCT/US2003/027772 WO2004078161A1 (en) 2003-02-28 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US10/660,202 2003-09-11
PCT/US2003/028982 WO2004026235A2 (en) 2002-09-20 2003-09-16 Pharmaceutical compositions with improved dissolution
AU2003267231 2003-09-16
PCT/US2003/041273 WO2004061433A1 (en) 2002-12-30 2003-12-24 Pharmaceutical compositions with improved dissolution

Publications (1)

Publication Number Publication Date
AU2003303591A1 true AU2003303591A1 (en) 2004-07-29

Family

ID=46124010

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003303591A Abandoned AU2003303591A1 (en) 2002-12-30 2003-12-24 Pharmaceutical compositions with improved dissolution

Country Status (4)

Country Link
EP (1) EP1579198A1 (en)
JP (1) JP5021934B2 (en)
AU (1) AU2003303591A1 (en)
CA (1) CA2511881C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
JP2015531785A (en) * 2012-09-13 2015-11-05 シービーエー・ファーマ・インコーポレイテッドＣｂａ Ｐｈａｒｍａ，Ｉｎｃ． Tetrandrine pharmaceutical formulation and method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11831A (en) * 1999-12-08 2005-08-23 Pharmacia Corp Polymorphic crystalline forms of celecoxib.
CZ20022332A3 (en) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sample assembly
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP2005535644A (en) * 2002-06-26 2005-11-24 ファルマシア コーポレイション Stable parenteral parecoxib liquid formulation
US20040092566A1 (en) * 2002-11-12 2004-05-13 Graneto Matthew J. Celecoxib prodrug

Also Published As

Publication number Publication date
JP5021934B2 (en) 2012-09-12
CA2511881C (en) 2013-06-25
JP2006517527A (en) 2006-07-27
EP1579198A1 (en) 2005-09-28
CA2511881A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
AU2009201465A1 (en) Pharmaceutical Compositions with Improved Dissolution
AU2003291103A1 (en) Pharmaceutical composition
GB2389530B (en) Pharmaceutical compositions
IL164547A0 (en) Pharmaceutical composition
AU2003250372A1 (en) Pharmaceutical composition
GB2391473B (en) Pharmaceutical compositions
AU2003260803A1 (en) Sustained release pharmaceutical composition
AU2003267231A1 (en) Pharmaceutical compositions with improved dissolution
GB0213481D0 (en) Pharmaceutical compositions
AU2003284460A1 (en) Medicinal composition
AU2003216503A1 (en) Stable pharmaceutical compositions
HK1065477A1 (en) Pharmaceutical composition
AU2003280799A1 (en) Medicinal composition
AU2003303591A1 (en) Pharmaceutical compositions with improved dissolution
AU2003280678A1 (en) Medicinal composition
PL370907A1 (en) Pharmaceutical compositions
AUPS188302A0 (en) Pharmaceutical composition
GB0217703D0 (en) Pharmaceutical composition
AU2002335161A1 (en) Medicinal composition
AUPS167102A0 (en) Pharmaceutical composition
AUPS124202A0 (en) Pharmaceutical composition
AU2003242346A1 (en) Drug composition
AU2003902322A0 (en) Pharmaceutical composition
AUPS008402A0 (en) Sustained release pharmaceutical composition
GB0211448D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase